Furthermore, our findings indicate a distinct advantage in combining p53 therapy, especially MDM2/X inhibition, with anti-PD-1 treatment over time, as evidenced by a synergistic effect leading to more effective tumor growth suppression and prolonged survival in a model partially responsive to immunotherapy. Here, MDM2 is linked to neoplasm.